DEFEROXAMINE MESYLATE- deferoxamine mesylate injection, powder, lyophilized, for solution Hospira, Inc.

Deferoxamine Mesylate for Injection, USP

Fliptop Vials

For subcutaneous, intramuscular or intravenous administration.

DESCRIPTION

Deferoxamine Mesylate for Injection, USP, is an iron-chelating agent, available in vials for intramuscular, subcutaneous, and intravenous administration. Deferoxamine mesylate is supplied as vials containing 500 mg and 2 g of deferoxamine mesylate USP in sterile, lyophilized form. Deferoxamine mesylate is *N*-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl] propionamido]pentyl]-3-[[5-(*N*-hydroxyacetamido)pentyl] carbamoyl] propionohydroxamic acid monomethanesulfonate (salt), and its structural formula is:

Deferoxamine mesylate USP is a white to off-white powder. It is freely soluble in water and slightly soluble in methanol. Its molecular weight is 656.79.

CLINICAL PHARMACOLOGY

Deferoxamine mesylate chelates iron by forming a stable complex that prevents the iron from entering into further chemical reactions. It readily chelates iron from ferritin and hemosiderin but not readily from transferrin; it does not combine with the iron from cytochromes and hemoglobin. Deferoxamine mesylate does not cause any demonstrable increase in the excretion of electrolytes or trace metals. Theoretically, 100 parts by weight of deferoxamine mesylate is capable of binding approximately 8.5 parts by weight of ferric iron.

Deferoxamine mesylate is metabolized principally by plasma enzymes, but the pathways have not yet been defined. The chelate is readily soluble in water and passes easily through the kidney, giving the urine a characteristic reddish color. Some is also excreted in the feces via the bile.

INDICATIONS AND USAGE

Deferoxamine Mesylate for Injection, USP is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias.

Acute Iron Intoxication

Deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric

Rx only

lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis.

Chronic Iron Overload

Deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). Long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis.

Iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated.

Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis, since phlebotomy is the method of choice for removing excess iron in this disorder.

CONTRAINDICATIONS

Known hypersensitivity to the active substance.

Deferoxamine mesylate is contraindicated in patients with severe renal disease or anuria, since the drug and the iron chelate are excreted primarily by the kidney (see **WARNINGS**).

WARNINGS

Ocular and auditory disturbances have been reported when deferoxamine mesylate was administered over prolonged periods of time, at high doses, or in patients with low ferritin levels. The ocular disturbances observed have been blurring of vision; cataracts after prolonged administration in chronic iron overload; decreased visual acuity including visual loss, visual defects, scotoma; impaired peripheral, color, and night vision; optic neuritis, cataracts, corneal opacities, and retinal pigmentary abnormalities. The auditory abnormalities reported have been tinnitus and hearing loss including high frequency sensorineural hearing loss. In most cases, both ocular and auditory disturbances were reversible upon immediate cessation of treatment (see **PRECAUTIONS/Information for Patients** and **ADVERSE REACTIONS/Special Senses**).

Visual acuity tests, slit-lamp examinations, funduscopy and audiometry are recommended periodically in patients treated for prolonged periods of time. Toxicity is more likely to be reversed if symptoms or test abnormalities are detected early.

Increases in serum creatinine (possibly dose-related), acute renal failure and renal tubular disorders, associated with the administration of deferoxamine, have been reported in postmarketing experience (see **ADVERSE REACTIONS**). Monitor patients for changes in renal function.

High doses of deferoxamine mesylate and concomitant low ferritin levels have also been associated with growth retardation. After reduction of deferoxamine mesylate dose, growth velocity may partially resume to pre-treatment rates (see **PRECAUTIONS/Pediatric Use**).

Adult respiratory distress syndrome, also reported in children, has been described following treatment with excessively high intravenous doses of deferoxamine mesylate in patients with acute iron intoxication or thalassemia.

PRECAUTIONS

General

Flushing of the skin, urticaria, hypotension, and shock has occurred in a few patients when deferoxamine mesylate was administered by rapid intravenous injection. THEREFORE,

DEFEROXAMINE MESYLATE SHOULD BE GIVEN INTRAMUSCULARLY OR BY SLOW SUBCUTANEOUS OR INTRAVENOUS INFUSION.

Iron overload increases susceptibility of patients to *Yersinia enterocolitica* and *Yersinia pseudotuberculosis* infections. In some rare cases, treatment with deferoxamine mesylate has enhanced this susceptibility, resulting in generalized infections by providing these bacteria with a siderophore otherwise missing. In such cases, deferoxamine mesylate treatment should be discontinued until the infection is resolved.

In patients receiving deferoxamine mesylate, rare cases of mucormycosis, some with a fatal outcome, have been reported. If any of the suspected signs or symptoms occur, deferoxamine mesylate should be discontinued, mycological tests carried out and appropriate treatment instituted immediately.

In patients with severe chronic iron overload, impairment of cardiac function has been reported following concomitant treatment with deferoxamine mesylate and high doses of vitamin C (more than 500 mg daily in adults). The cardiac dysfunction was reversible when vitamin C was discontinued. The following precautions should be taken when vitamin C and deferoxamine mesylate are to be used concomitantly:

- Vitamin C supplements should not be given to patients with cardiac failure.
- Start supplemental vitamin C only after an initial month of regular treatment with deferoxamine mesylate.
- Give vitamin C only if the patient is receiving deferoxamine mesylate regularly, ideally soon after setting up the infusion pump.
- Do not exceed a daily vitamin C dose of 200 mg in adults, given in divided doses.
- Clinical monitoring of cardiac function is advisable during such combined therapy.

In patients with aluminum-related encephalopathy and receiving dialysis, deferoxamine mesylate may cause neurological dysfunction (seizures), possibly due to an acute increase in circulating aluminum (see **ADVERSE REACTIONS**). Deferoxamine mesylate may precipitate the onset of dialysis dementia. Treatment with deferoxamine mesylate in the presence of aluminum overload may result in decreased serum calcium and aggravation of hyperparathyroidism.

Drug Interactions

Vitamin C: Patients with iron overload usually become vitamin C deficient, probably because iron oxidizes the vitamin. As an adjuvant to iron chelation therapy, vitamin C in doses up to 200 mg for adults may be given in divided doses, starting after an initial month of regular treatment with deferoxamine mesylate (see **PRECAUTIONS**). Vitamin C increases availability of iron for chelation. In general, 50 mg daily suffices for children under 10 years old and 100 mg daily for older children. Larger doses of vitamin C fail to produce any additional increase in excretion of iron complex.

Prochlorperazine: Concurrent treatment with deferoxamine mesylate and prochlorperazine, a phenothiazine derivative, may lead to temporary impairment of consciousness.

Gallium-67: Imaging results may be distorted because of the rapid urinary excretion of deferoxamine mesylate-bound gallium-67. Discontinuation of deferoxamine mesylate 48 hours prior to scintigraphy is advisable.

Information for Patients

Patients experiencing dizziness or other nervous system disturbances, or impairment of vision or hearing, should refrain from driving or operating potentially hazardous machines (see **ADVERSE REACTIONS**).

Patients should be informed that occasionally their urine may show a reddish discoloration.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term carcinogenicity studies in animals have not been performed with deferoxamine mesylate.

Cytotoxicity may occur, since deferoxamine mesylate has been shown to inhibit DNA synthesis *in vitro*.

Delayed ossification in mice and skeletal anomalies in rabbits were observed after deferoxamine mesylate was administered in daily doses up to 4.5 times the maximum daily human dose. No adverse effects were observed in similar studies in rats.

There are no adequate and well-controlled studies in pregnant women. Deferoxamine mesylate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when deferoxamine mesylate is administered to a nursing woman.

Pediatric Use

Pediatric patients receiving deferoxamine mesylate should be monitored for body weight and growth every 3 months.

Safety and effectiveness in pediatric patients under the age of 3 years have not been established (see **INDICATIONS AND USAGE, WARNINGS, PRECAUTIONS/Drug Interactions**/*Vitamin C*, and **ADVERSE REACTIONS**).

Geriatric Use

Clinical Studies of deferoxamine mesylate did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from the younger subjects. Postmarketing reports suggest a possible trend for an increased risk of eye disorders in the geriatric population, specifically the occurrence of color blindness, maculopathy, and scotoma. However, it is unclear if these eye disorders were dose related. Although the number of reports was very small, certain elderly patients may be predisposed to eye disorders when taking deferoxamine mesylate. Postmarketing reports also suggest that there may be an increased risk of deafness and hearing loss in the geriatric population (see **ADVERSE REACTIONS**). In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Hepatic Impairment

No studies have been performed in patients with hepatic impairment.

ADVERSE REACTIONS

The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency.

At the Injection Site: Localized irritation, pain, burning, swelling, induration, infiltration, pruritus, erythema, wheal formation, eschar, crust, vesicles, local edema. Injection site reactions may be associated with systemic allergic reactions (see *Body as a Whole*, below).

Hypersensitivity Reactions and Systemic Allergic Reactions: Generalized rash, urticaria, anaphylactic reaction with or without shock, angioedema.

Body as a Whole: Local injection site reactions may be accompanied by systemic reactions like arthralgia, fever, headache, myalgia, nausea, vomiting, abdominal pain, or asthma.

Infections with *Yersinia* and *Mucormycosis* have been reported in association with deferoxamine mesylate use (see **PRECAUTIONS**).

Cardiovascular: Tachycardia, hypotension, shock.

Digestive: Abdominal discomfort, diarrhea, nausea, vomiting.

Hematologic: Blood dyscrasia (thrombocytopenia, leukopenia).

Hepatic: Increased transaminases, hepatic dysfunction.

Musculoskeletal: Muscle spasms. Growth retardation and bone changes (e.g., metaphyseal dysplasia) are common in chelated patients given doses above 60 mg/kg, especially those who begin iron chelation in the first three years of life. If doses are kept to 40 mg/kg or below, the risk may be reduced (see **WARNINGS, PRECAUTIONS/Pediatric Use**).

Nervous System: Neurological disturbances including dizziness, peripheral sensory, motor, or mixed neuropathy, paresthesias, seizures; exacerbation or precipitation of aluminum-related dialysis encephalopathy (see **PRECAUTIONS/Information for Patients**).

Special Senses: High-frequency sensorineural hearing loss and/or tinnitus are uncommon if dosage guidelines are not exceeded and if dose is reduced when ferritin levels decline. Visual disturbances are rare if dosage guidelines are not exceeded. These may include decreased acuity, blurred vision, loss of vision, dyschromatopsia, night blindness, visual field defects, scotoma, retinopathy (pigmentary degeneration), optic neuritis, and cataracts (see **WARNINGS**).

Respiratory: Acute respiratory distress syndrome (with dyspnea, cyanosis, and/or interstitial infiltrates) (see WARNINGS).

Skin: Very rare generalized rash.

Urogenital: Dysuria, acute renal failure, increased serum creatinine and renal tubular disorders (see **CONTRAINDICATIONS** and **WARNINGS**).

Postmarketing Reports

There are postmarketing reports of deferoxamine-associated renal dysfunction, including renal failure. Monitor patients for changes in renal function (e.g., increased serum creatinine).

OVERDOSAGE

Acute Toxicity

Intravenous LD₅₀s (mg/kg): mice, 287; rats, 329.

Signs and Symptoms

Inadvertent administration of an overdose or inadvertent intravenous bolus administration/rapid intravenous infusion may be associated with hypotension, tachycardia and gastrointestinal disturbances; acute but transient loss of vision, aphasia, agitation, headache, nausea, pallor, CNS depression including coma, bradycardia and acute renal failure have been reported.

Acute respiratory distress syndrome has been reported following treatment with excessively high intravenous doses of Deferoxamine Mesylate for Injection, USP in patients with acute iron intoxication and in patients with thalassemia.

Treatment

There is no specific antidote. Deferoxamine mesylate should be discontinued and appropriate symptomatic measures undertaken.

Deferoxamine mesylate is readily dialyzable.

DOSAGE AND ADMINISTRATION

Acute Iron Intoxication

Intramuscular Administration

This route is preferred and should be used for ALL PATIENTS NOT IN SHOCK.

A dose of 1,000 mg should be administered initially. This may be followed by 500 mg every 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered every 4 to 12 hours. The total amount administered should not exceed 6,000 mg in 24 hours. For reconstitution instructions for intramuscular administration see Table 1.

Intravenous Administration

THIS ROUTE SHOULD BE USED ONLY FOR PATIENTS IN A STATE OF CARDIOVASCULAR COLLAPSE AND THEN ONLY BY SLOW INFUSION. THE RATE OF INFUSION SHOULD NOT EXCEED 15 MG/KG/HR FOR THE FIRST 1,000 MG ADMINISTERED. SUBSEQUENT IV DOSING, IF NEEDED, MUST BE AT A SLOWER RATE, NOT TO EXCEED 125 MG/HR.

For reconstitution instructions for intravenous administration see Table 2. The reconstituted solution is added to physiologic saline, (e.g., 0.9% sodium chloride, 0.45% sodium chloride), glucose in water, or Ringer's lactate solution.

An initial dose of 1,000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4 to 12 hours. The total amount administered should not exceed 6,000 mg in 24 hours.

As soon as the clinical condition of the patient permits, intravenous administration should be discontinued and the drug should be administered intramuscularly.

Chronic Iron Overload

Subcutaneous Administration

A daily dose of 1,000 to 2,000 mg (20 to 40 mg/kg/day) should be administered over 8 to 24 hours, utilizing a small portable pump capable of providing continuous mini-infusion. The duration of infusion must be individualized. In some patients, as much iron will be excreted after a short infusion of 8 to 12 hours as with the same dose given over 24 hours. For reconstitution instructions for subcutaneous administration see Table 3.

Intravenous Administration

The standard recommended method of Deferoxamine Mesylate for Injection, USP administration is via slow subcutaneous infusion over 8 to 12 hours. In patients with intravenous access, the daily dose of Deferoxamine Mesylate for Injection, USP can be administered intravenously. The standard dose is 20 to 40 mg/kg/day for children and 40 to 50 mg/kg/day over 8 to 12 hours in adults for 5 to 7 days per week. In children, average doses should not exceed 40 mg/kg/day until growth has ceased. In adults, average doses should not exceed 60 mg/kg/day. The intravenous infusion rate should not exceed 15 mg/kg/hour. For reconstitution instructions for intravenous administration see Table 2.

In patients who are poorly compliant, Deferoxamine Mesylate for Injection, USP may be administered prior to or following same day blood transfusion (for example 1 gram over 4 hours on the day of transfusion); however, the contribution of this mode of administration to iron balance is limited. Deferoxamine Mesylate for Injection, USP should not be administered concurrently with the blood transfusion as this can lead to errors in interpreting side effects such as rash, anaphylaxis and hypotension.

Intramuscular Administration

A daily dose of 500 to 1,000 mg may be administered intramuscularly. The total daily dose should not exceed 1,000 mg. For reconstitution instructions for intramuscular administration see Table 1.

RECO	ONSTITUTE DEFEROXAMINE N STERILE WATE	AESYLATE FOR INJE R FOR INJECTION	CTION, USP WITH
Vial Size	Amount of Sterile Water for Injection Required for Reconstitution	Total Drug Content after Reconstitution	Final Concentration per mL after Reconstitution
500 mg	2 mL	500 mg/2.35 mL	213 mg/mL
2 grams	8 mL	2 grams/9.4 mL	213 mg/mL

Table 1: Preparation for Intramuscular Administration

Table 2: Preparation for Intravenous Administration

RECO	RECONSTITUTE DEFEROXAMINE MESYLATE FOR INJECTION, USP WITH STERILE WATER FOR INJECTION				
Vial Size	Amount of Sterile Water for Injection Required for Reconstitution	Total Drug Content after Reconstitution	Final Concentration per mL after Reconstitution		
500 mg	5 mL	500 mg/5.3 mL	95 mg/mL		
2 grams	20 mL	2 grams/21.1 mL	95 mg/mL		

Table 3: Preparation for Subcutaneous Administration

RECO	RECONSTITUTE DEFEROXAMINE MESYLATE FOR INJECTION, USP WITH STERILE WATER FOR INJECTION				
Vial Size	Amount of Sterile Water for Injection Required for Reconstitution	Total Drug Content after Reconstitution	Final Concentration per mL after Reconstitution		
500 mg	5 mL	500 mg/5.3 mL	95 mg/mL		
2 grams	20 mL	2 grams/21.1 mL	95 mg/mL		

The reconstituted deferoxamine mesylate solution is an isotonic, clear and colorless to slightly yellowish-colored solution. The drug should be completely dissolved before the solution is withdrawn. Deferoxamine Mesylate for Injection, USP reconstituted with Sterile Water for Injection **IS FOR SINGLE-DOSE ONLY. Discard unused portion.**

The product should be used immediately after reconstitution (commencement of treatment within 3 hours) for microbiological safety. When reconstitution is carried out under validated aseptic conditions (in a sterile laminar flow hood using aseptic technique), the product may be stored at room temperature for a maximum period of 24 hours before use. Do not refrigerate reconstituted solution. Reconstituting Deferoxamine Mesylate for Injection, USP in solvents or under conditions other than indicated may result in precipitation. Turbid solutions should not be used.

HOW SUPPLIED

Unit of Sale	Concentration	
NDC 0409-2336-10	500 mg	
Carton of 4 Single-dose		
Fliptop vials		
NDC 0409-2337-25	2 g	

Carton of 4 Single-dose Fliptop vials

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] For single-dose only. Discard unused portion.



Distributed by Hospira, Inc., Lake Forest, IL 60045 USA LAB-1006-2.0 Revised: 10/2018

PRINCIPAL DISPLAY PANEL - 500 mg Vial Label

Single-dose Vial Rx only

Deferoxamine Mesylate for Injection, USP

500 mg/vial

INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS USE

Distributed by Hospira, Inc., Lake Forest, IL 60045 USA

Sing	gle-dose Vial	Rx only	NDC 0409	-2336-01	886		
$\equiv D$	eferoxami	ne Red	onstituted Ex ert. Turbid solut	p.: See tions	9 4		
🖞 for	esylate Injection, USP Dmg/vial	sho 20 t USF Ten	uld not be used to 25°C (68 to 7 P Controlled Ro operature.] Disc	d. Store at 7°F). [See om	233	Α ΥΥ	
INT	RAVENOUS, RAMUSCULAR, SU ributed by pira, Inc., Lake Forest,	unu IBCUTANE	sed portion.	Hospira	P A A 1 2 4 LOT/EXP	##### DMMMYY	


PRINCIPAL DISPLAY PANEL - 500 mg Vial Carton


4 Single-dose Vials Rx only NDC 0409-2336-10 Contains 4 of NDC 0409-2336-01 Deferoxamine Mesylate for Injection, USP

500 mg/vial

Hospira

Each vial contains deferoxamine mesylate USP, 500 mg in lyophilized form. INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS USE Discard unused portion.





PRINCIPAL DISPLAY PANEL - 2 g Vial Label

Fliptop Vial Rx only

Deferoxamine Mesylate for Injection, USP

2 g/vial

For single-dose only.

For S.C., I.M. or I.V. Use



PRINCIPAL DISPLAY PANEL - 2 g Vial Carton

4 Fliptop Vials Rx only NDC 0409-2337-25 Contains 4 of NDC 0409-2337-15


Deferoxamine Mesylate for Injection, USP

2 g/vial

Hospira

Each vial contains deferoxamine mesylate USP, 2 g in lyophilized form. For subcutaneous, intramuscular or intravenous administration.

For single-dose only. Discard unused portion. Distributed by Hospira, Inc., Lake Forest, IL 60045 USA





	ylate injection, j	oowder, lyophilized, for solution				
Product Inform	ation					
Product Type		HUMAN PRESCRIPTION DRUG		Item Code (Source)	ND 233	0C:0409- 36
Route of Administ	ration	INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS				
Active Ingredie	nt/Active Moi	etv				
		redient Name		Basis of S	Strength	Strengt
DEFERO XAMINE M UNII:J06 Y7MXW4D)	-	9TKO7EO6K) (DEFEROXAMINE -		DEFEROXAMI MESYLATE	-	500 mg
Inactive Ingred		ngredient Name			Strength	
WATER (UNII: 059Q		8				
(FUKOUKJ					
	FUKUUR)					
Packaging	FURCUR)	Package Description	Marl	keting Start Date		ting End ate
Packaging # Item Code	4 in 1 CARTON	Package Description	Marl 04/30/20	Date		-
Packaging # Item Code 1 NDC:0409-2336- 10	4 in 1 CARTON	Package Description GLE-USE; Type 0: Not a Combination		Date		-
Packaging Item Code 1 NDC:0409-2336- 10 1 NDC:0409-2336- 01	4 in 1 CARTON 1 in 1 VIAL, SING Product			Date		-
H Item Code 1 NDC:0409-2336- 10 1 NDC:0409-2336-	4 in 1 CARTON 1 in 1 VIAL, SING Product		0 4/30/20	Date	D	-

DEFEROXAMINE MESYLATE

deferoxamine mesylate injection, powder, lyophilized, for solution

INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS Subcutaneous Subcutaneous Subcutaneous Subcutaneous Subcutaneous Subcutaneous Subcutaneous Strength Strength Strength Strength Strength Strength UNE JOS OF VAXWAD) Strength Strength Ingredient Name Strength Marketing Start Marketing Ene Strength Strength Marketing Ene Strength Strength Naccus Package Description 03/31/2015 Strength Naccus Package Description 03/31/2015 O NDC:0409-2337: 1 In 1 VIAL, SINGLE-USE; Type 0: Not a Combination O O NDC:0409-2337: Application Number or Monograph Citation Marketing Category Application Number or Monograph Citation	Product T ype		HUMAN PRESCRIPTION DRUG		Item Code (Source)	-	NDC:0409- 337
Ingredient Name Basis of Strength Strength DEFERO XAMINE MES YLATE (UNII: V9TKO7EO6K) (DEFERO XAMINE - UNIEJO6 Y7MXW4D) DEFERO XAMINE MES YLATE 2 g Ingredients Ingredients Ingredient Name 2 g Ingredient Name Strength Ingredient Name Marketing Start Ingredient Start Date Ingredient Name Ingredient Name Ingredient Name Ingredient Name Ingredient Name Ingredient Name </th <th>Route of Administra</th> <th>ation</th> <th></th> <th></th> <th></th> <th></th> <th></th>	Route of Administra	ation					
Ingredient Name Basis of Strength Strength DEFERO XAMINE MES YLATE (UNII: V9TKO7EO6K) (DEFERO XAMINE - UNIEJO6 Y7MXW4D) DEFERO XAMINE MES YLATE 2 g Ingredients Ingredients Ingredient Name 2 g Ingredient Name Strength Ingredient Name Marketing Start Ingredient Start Date Ingredient Name Ingredient Name Ingredient Name Ingredient Name Ingredient Name Ingredient Name </th <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>							
DEFERO XAMINE MESYLATE (UNII: V9TK07E06K) (DEFERO XAMINE - DEFERO XAMINE MESYLATE 2 g Imactive Ingredients Ingredient Name Strength WATER (UNII: 059QF0K00R) Image: Strength Image: Strength Image: Strength Image: Strength Image: Strength Image: Stren	Active Ingredier	nt/Active Moi	ety				
UNIE: J06 ¥7MX W4D) MES YLATE 2 g Imactive Ingredients Ingredient Name Strength WATER (UNIE: 059QF0KOOR) Strength 1 Marketing Start Date Marketing Entropate 1 NDC: 0409-2337- 25 4 in 1 CARTON 03/31/2005 Marketing Entropate 1 NDC: 0409-2337- 15 1 in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product 03/31/2005 1 Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing Entropate		Ing	redient Name		Basis of S	Strength	Strength
Ingredient Name Strength Watter (UNII: 059QF0K0R) Strength Impredient Name Marketing Start Impredient Start Date Marketing End Date Impredient Name Strength Impredient Name Out Impredient Name Strength Impredient Name Out Impredient Name Out Impredient Name Out		SYLATE (UNII: V	9TKO7EO6K) (DEFEROXAMINE -			NE	2 g
Ingredient Name Strength Strength W TER (UNII: 059QFULUESULUESULUESULUESULUESULUESULUESULUE							
WATER (UNIE: 059 QF0K00R) Packaging Item Code Package Description Marketing Start Date Marketing Start Date Marketing Start Date Marketing Start Date Marketing Start Date Marketing Start Date Marketing Start Date Marketing Start Date Marketing Start Date Marketing Start Date Marketing Start Date Marketing Information Marketing Categove Application Number or Monograph Citation Marketing Start Date	Inactive Ingredie	ents					
Warketing Start Date Marketing Start Date # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0409-2337- 25 4 in 1 CARTON 03/31/2005 03/31/2005 1 NDC:0409-2337- 15 1 in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product 03/31/2005 Vertex sting Information Warketing Category Application Number or Monograph Citation		_	••			C	- L
# Item Code Package Description Marketing Start Date Marketing Entry Date 1 NDC:0409-2337- 2.5 4 in 1 CARTON 03/31/2005 03/31/2005 1 NDC:0409-2337- 1.5 1 in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product 03/31/2005 Warketing Inf VIAL, SINGLE-USE; Type 0: Not a Combination Warketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date			ngredient Name			Strengt	.11
# Item Code Package Description Marketing Start Date Marketing Entry Date 1 NDC:0409-2337- 25 4 in 1 CARTON 03/31/2005 03/31/2005 1 NDC:0409-2337- 15 1 in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product 03/31/2005 Varketing Information Product 1 Narketing Category Application Number or Monograph Citation	WATER (UNII: 059QF		ngredient Name			Strengt	.11
** Them Code Package Description Date Date 1 NDC:0409-2337- 25 4 in 1 CARTON 03/31/2005 03/31/2005 1 NDC:0409-2337- 15 1 in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product 03/31/2005 Varketing Information Warketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date	WATER (UNII: 059QF		ngredient Name			Streng	.11
I 25 4 in TCARTON 03/31/2005 I NDC:0409-2337- 15 1 in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product 03/31/2005 I NDC:0409-2337- 15 1 in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product Image: Comparison of Comparison			ngredient Name			Streng	
I 15 Product II II Product III IIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Packaging			Mark		Mark	eting End
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date	Packaging # Item Code 1 NDC:0409-2337-	OKOOR)			Date	Mark	eting End
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Da	H Item Code 1 NDC:0409-2337- 25 1 NDC:0409-2337- 25	OKOOR) 4 in 1 CARTON 1 in 1 VIAL, SINC	Package Description		Date	Mark	eting End
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Da	H Item Code 1 NDC:0409-2337- 25 1 NDC:0409-2337- 25	OKOOR) 4 in 1 CARTON 1 in 1 VIAL, SINC	Package Description		Date	Mark	eting End
	Packaging # Item Code 1 NDC:0409-2337- 25 1 NDC:0409-2337- 15	OKOOR) 4 in 1 CARTON 1 in 1 VIAL, SING Product	Package Description		Date	Mark	eting End
ANDA ANDA076019 03/31/2005	Packaging # Item Code 1 NDC:0409-2337- 25 1 NDC:0409-2337- 15	OKOOR) 4 in 1 CARTON 1 in 1 VIAL, SING Product	Package Description		Date	Mark	eting End
	Packaging # Item Code 1 NDC:0409-2337- 25 1 NDC:0409-2337- 15 NDC:0409-2337- 15 NDC:0409-2337- 15	OKOOR) 4 in 1 CARTON 1 in 1 VIAL, SINC Product formation	Package Description RLE-USE; Type 0: Not a Combination	03/31/20	Date 05	Mark	eting End Date

Labeler - Hospira, Inc. (141588017)

Revised: 3/2019

Hospira, Inc.